European Journal of Cancer
Volume 42, Issue 5 , Pages 621-628 , March 2006

Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer

  • Yoland Antill

      Affiliations

    • Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A’Beckett Street, Melbourne 8006, Vic., Australia
    • ,
  • John Reynolds

      Affiliations

    • Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A’Beckett Street, Melbourne 8006, Vic., Australia
    • ,
  • Mary-Anne Young

      Affiliations

    • Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A’Beckett Street, Melbourne 8006, Vic., Australia
    • ,
  • Judy Kirk

      Affiliations

    • Westmead Hospital, Sydney, NSW, Australia
    • ,
  • Katherine Tucker

      Affiliations

    • Prince of Wales Hospital, Sydney, NSW, Australia
    • ,
  • Tarli Bogtstra

      Affiliations

    • Monash Medical Centre, Melbourne, Vic., Australia
    • ,
  • Shirley Wong

      Affiliations

    • Royal Melbourne Hospital, Vic., Australia
    • ,
  • Tracy Dudding

      Affiliations

    • Hunter Genetics, Newcastle, NSW, Australia
    • ,
  • Juliana Di Iulio

      Affiliations

    • Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A’Beckett Street, Melbourne 8006, Vic., Australia
    • ,
  • Kelly-Anne Phillips

      Affiliations

    • Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A’Beckett Street, Melbourne 8006, Vic., Australia
    • The University of Melbourne, Department of Medicine, St. Vincent’s Hospital, Vic., Australia
    • Corresponding Author InformationCorresponding author: Tel.: +61 3 96561701; fax: +61 3 96561408.

Received 16 August 2005 ,Revised 7 November 2005 ,Accepted 11 November 2006.

References 

  1. In:  Ries LEM,  Kosary CL, et al. editor. SEER cancer statistics review. Bethesda: National Cancer Institute; 2005;p. 1975–2002
  2. Cancer in Australia 2001. Canberra: Australian Institute of Health and Welfare, Australasian Association of Cancer Registries, Report No. 28, December 2001.
  3. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–1130
  4. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22(6):1055–1062
  5. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159–164
  6. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340(2):77–84
  7. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609–1615
  8. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616–1622
  9. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91(17):1475–1479
  10. Lerman C, Hughes C, Croyle RT, et al. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med. 2000;31(1):75–80
  11. Botkin JR, Smith KR, Croyle RT, et al. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post-testing. Am J Med Genet A. 2003;118(3):201–209
  12. Watson M, Foster C, Eeles R, et al. Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort. Br J Cancer. 2004;91(10):1787–1794
  13. Julian-Reynier CM, Bouchard LJ, Evans DG, et al. Women’s attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer. 2001;92(4):959–968
  14. Eisinger F, Stoppa-Lyonnet D, Lasset C, et al. Comparison of physicians’ and cancer prone women’s attitudes about breast/ovarian prophylactic surgery. Results from two national surveys. Fam Cancer. 2001;1(3–4):157–162
  15. Meiser B, Butow P, Barratt A, et al. Breast cancer screening uptake in women at increased risk of developing hereditary breast cancer. Breast Cancer Res Treat. 2000;59(2):101–111
  16. Eisinger F, Huiart L, Sobol H. The choice of bilateral prophylactic mastectomy. J Clin Oncol. 2005;23(6):1330–1331author reply 1331–2
  17. Sauven P. Guidelines for the management of women at increased familial risk of breast cancer. Eur J Cancer. 2004;40(5):653–665
  18. Antill Y, Phillips K. Ovarian cancer screening for high risk women. In:  Gershenson D,  McGuire W,  Gore M,  Thomas G,  Quinn M editor. Gynaecological cancers: Controversies in management. Philadelphia: Elsevier; 2004;
  19. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351(5):427–437
  20. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005;365(9473):1769–1778
  21. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292(11):1317–1325
  22. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360(9336):817–824
  23. Familial aspects of cancer: a guide to clinical practice. Canberra: Biotext, NHMRC; 1999.
  24. www.ibis-trials.org.
  25. Osborne RH, Hopper JL, Kirk JA, et al. kConFab: a research resource of Australasian breast cancer families. Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. Med J Aust. 2000;172(9):463–464
  26. Evans DG, Burnell LD, Hopwood P, et al. Perception of risk in women with a family history of breast cancer. Br J Cancer. 1993;67(3):612–614
  27. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med. 1979;41(3):209–218
  28. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002;20(5):1260–1268
  29. Scott CI, Iorgulescu DG, Thorne HJ, et al. Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy. Clin Genet. 2003;64(2):111–121
  30. Lodder LN, Frets PG, Trijsburg RW, et al. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat. 2002;73(2):97–112
  31. Bouchard L, Blancquaert I, Eisinger F, et al. Prevention and genetic testing for breast cancer: variations in medical decisions. Soc Sci Med. 2004;58(6):1085–1096
  32. Lobb EA, Butow PN, Meiser B, et al. Tailoring communication in consultations with women from high risk breast cancer families. Br J Cancer. 2002;87(5):502–508
  33. Lobb E, Meiser B. Genetic counselling and prophylactic surgery in women from families with hereditary breast or ovarian cancer. Lancet. 2004;363(9424):1841–1842
  34. Familial aspects of ovarian cancer. Clinical practice guidelines for the management of women with epithelial ovarian cancer: NHMRC; 2004.
  35. McAllister M. Personal theories of inheritance, coping strategies, risk perception and engagement in hereditary non-polyposis colon cancer families offered genetic testing. Clin Genet. 2003;64(3):179–189
  36. d’Agincourt-Canning L. The effect of experiential knowledge on construction of risk perception in hereditary breast/ovarian cancer. J Genet Couns. 2005;14(1):55–69
  37. Newman B, Mu H, Butler LM, et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA. 1998;279(12):915–921
  38. Metcalfe KA, Narod SA. Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy. J Natl Cancer Inst. 2002;94(20):1564–1569
  39. Metcalfe KA, Esplen MJ, Goel V, et al. Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy. Psychooncology. 2004;13(1):14–25

PII: S0959-8049(05)01099-3

doi: 10.1016/j.ejca.2005.11.020

European Journal of Cancer
Volume 42, Issue 5 , Pages 621-628 , March 2006

Article Tools